Ling Guo

8.4k total citations
168 papers, 3.4k citations indexed

About

Ling Guo is a scholar working on Otorhinolaryngology, Oncology and Molecular Biology. According to data from OpenAlex, Ling Guo has authored 168 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Otorhinolaryngology, 55 papers in Oncology and 53 papers in Molecular Biology. Recurrent topics in Ling Guo's work include Head and Neck Cancer Studies (74 papers), Head and Neck Surgical Oncology (34 papers) and Cancer-related molecular mechanisms research (21 papers). Ling Guo is often cited by papers focused on Head and Neck Cancer Studies (74 papers), Head and Neck Surgical Oncology (34 papers) and Cancer-related molecular mechanisms research (21 papers). Ling Guo collaborates with scholars based in China, United States and Canada. Ling Guo's co-authors include Ming‐Yuan Chen, Ming‐Huang Hong, Min Feng, Xiang Guo, Hai-Qiang Mai, Huan‐Xin Lin, Xiong Zou, Cuifeng Wang, Xin Hua and Rou Jiang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ling Guo

164 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ling Guo China	33	1.3k	1.2k	1.2k	890	798	168	3.4k
Li‐Yu Lee Taiwan	38	796 0.6×	1.3k 1.1×	2.2k 1.9×	509 0.6×	1.7k 2.2×	134	4.0k
Mona F. Melhem United States	30	2.0k 1.6×	1.9k 1.6×	490 0.4×	501 0.6×	588 0.7×	45	4.5k
Jason Chia‐Hsien Cheng Taiwan	37	859 0.7×	1.0k 0.9×	451 0.4×	715 0.8×	1.2k 1.5×	208	4.5k
Tomoya Yokota Japan	31	799 0.6×	1.4k 1.2×	400 0.3×	325 0.4×	1.1k 1.4×	186	3.3k
Thomas J. Ow United States	23	714 0.6×	695 0.6×	514 0.4×	395 0.4×	654 0.8×	87	2.0k
Guy Andry Belgium	29	729 0.6×	755 0.6×	436 0.4×	374 0.4×	861 1.1×	113	2.6k
Andrew C. Birkeland United States	27	626 0.5×	533 0.4×	569 0.5×	331 0.4×	544 0.7×	116	2.0k
Pierre Saintigny France	28	1.2k 0.9×	996 0.8×	296 0.3×	704 0.8×	236 0.3×	131	2.5k
Zhen‐Yu He China	28	874 0.7×	1.2k 1.0×	182 0.2×	1.0k 1.2×	763 1.0×	180	3.3k
Ming Zhang China	29	751 0.6×	1.2k 1.0×	217 0.2×	466 0.5×	637 0.8×	167	2.7k

Countries citing papers authored by Ling Guo

Since Specialization

Citations

This map shows the geographic impact of Ling Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Guo more than expected).

Fields of papers citing papers by Ling Guo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ling Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Guo. The network helps show where Ling Guo may publish in the future.

Co-authorship network of co-authors of Ling Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Ling Guo. A scholar is included among the top collaborators of Ling Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ling Guo. Ling Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guo, Ling, et al.. (2026). Optimizing butorphanol-dexmedetomidine dosing for managing catheter-related bladder discomfort post-anesthesia: a randomized trial. Scientific Reports. 16(1). 4788–4788.

Guo, Ling, et al.. (2025). The development of disaster preparedness education for public: a scoping review. BMC Public Health. 25(1). 645–645. 8 indexed citations

Chen, Qiuyan, Hai‐Qiang Mai, Shan-Shan Guo, et al.. (2024). Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 6072–6072. 1 indexed citations

Mai, Hai‐Qiang, Shanshan Guo, Li-Ting Liu, et al.. (2024). Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 6084–6084. 3 indexed citations

Guo, Jia, Chao Lin, Qi Jiang, et al.. (2023). Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma. Oral Oncology. 146. 106574–106574. 1 indexed citations

Wang, Ying, et al.. (2023). Neutrophil extracellular traps (NETs)-related lncRNAs signature for predicting prognosis and the immune microenvironment in breast cancer. Frontiers in Cell and Developmental Biology. 11. 1117637–1117637. 23 indexed citations

Luo, Dong–Hua, Xiaoyun Li, Shanshan Guo, et al.. (2023). Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA–IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial. The Lancet Regional Health - Western Pacific. 40. 100895–100895. 5 indexed citations

Li, Yuan, Xiaofei Lv, Da-Feng Lin, et al.. (2023). Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nature Communications. 14(1). 4893–4893. 25 indexed citations

Guo, Shanshan, Li‐Ting Liu, Qiuyan Chen, et al.. (2021). Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study. Cancer Biology and Medicine. 19(4). 551–564. 8 indexed citations

10.

Liu, Li‐Ting, Yu-Jing Liang, Shanshan Guo, et al.. (2020). Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology. 12. 3863543254–3863543254. 6 indexed citations

11.

Guo, Ling, et al.. (2019). Tunneling Nanotubular Expressways for Ultrafast and Accurate M1 Macrophage Delivery of Anticancer Drugs to Metastatic Ovarian Carcinoma. ACS Nano. 13(2). 1078–1096. 85 indexed citations

12.

Wu, Jiamin, Zhi Li, Ling Guo, et al.. (2018). A Glutamine-Rich Carrier Efficiently Delivers Anti-CD47 siRNA Driven by a “Glutamine Trap” To Inhibit Lung Cancer Cell Growth. Molecular Pharmaceutics. 15(8). 3032–3045. 33 indexed citations

13.

Yang, Qi, Meng-Xia Zhang, Xiong Zou, et al.. (2017). A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy. Clinical Cancer Research. 24(3). 648–658. 26 indexed citations

14.

Zheng, Li-Sheng, Yun Cao, Li-Xia Peng, et al.. (2016). SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor. Cancer Research. 77(2). 579–589. 46 indexed citations

15.

Wang, Shufeng, Ling Guo, Dong Liu, Wei Liu, & Yuzhang Wu. (2016). HLAsupE: an integrated database of HLA supertype-specific epitopes to aid in the development of vaccines with broad coverage of the human population. BMC Immunology. 17(1). 17–17. 11 indexed citations

16.

Yang, Qi, Huan‐Xin Lin, Shu‐Biao Wu, et al.. (2015). Prostate Tumor Overexpressed 1 (PTOV1) Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Poor Survival Outcomes. PLoS ONE. 10(8). e0136448–e0136448. 16 indexed citations

17.

He, Zhen‐Yu, Juan Zhou, Jiayuan Sun, et al.. (2014). Benefit of Post-mastectomy Radiotherapy of the Supra-/infraclavicular Lymphatic Drainage Area in Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention. 15(14). 5557–5563. 2 indexed citations

18.

Lin, Huan-Xin, Yi-Jun Hua, Qiu-Yan Chen, et al.. (2013). Randomized study of sinusoidal chronomodulated versus flat intermittent induction chemotherapy with cisplatin and 5-fluorouracil followed by traditional radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer. 32(9). 502–511. 23 indexed citations

19.

Liao, Wenting, et al.. (2011). Astrocyte elevated gene-1 (AEG-1) is a marker for aggressive salivary gland carcinoma. Journal of Translational Medicine. 9(1). 205–205. 29 indexed citations

20.

Huang, Pei-Yu, Hai‐Qiang Mai, Dong–Hua Luo, et al.. (2009). Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer. 28(10). 1033–1042. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact